Achievements and futures of immune checkpoint inhibitors in non-small cell lung cancer

Non-small cell lung cancer (NSCLC) has been threatening human health for years. Cytotoxicity-based chemotherapy seems to reach plateau in NSCLC treatment. Immunotherapy with immune checkpoint inhibitors (ICIs) against programmed cell death 1 (PD-1/L1) axis are to provide long-term survival benefits...

Descripción completa

Detalles Bibliográficos
Autores principales: Qiu, Zhenbin, Chen, Zihao, Zhang, Chao, Zhong, Wenzhao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6706908/
https://www.ncbi.nlm.nih.gov/pubmed/31463163
http://dx.doi.org/10.1186/s40164-019-0143-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6706908/
https://www.ncbi.nlm.nih.gov/pubmed/31463163
http://dx.doi.org/10.1186/s40164-019-0143-z

Ejemplares similares